Annual Review of Medicine · Nov 16, 2026

RNA Therapeutics in Cardiovascular Medicine: From Molecular Mechanisms to Clinical Practice

By Holley CL

RNA therapeutics are an exciting class of medications that target RNA and/or are themselves made from RNA. Most RNA therapeutics that have been approved for clinical use are antisense oligonucleotides or small interfering RNAs. To date, eight RNA therapeutics with cardiovascular relevance have received US Food and Drug Administration approval, but not all of them have specific indications for treating cardiovascular disease. There is a promising pipeline of additional cardiovascular RNA therapies targeting lipoprotein(a), angiopoietin-like protein 3, and angiotensinogen. Chemical modifications to therapeutic nucleic acids are important for conferring nuclease resistance and limiting immunostimulation in vivo, and enhanced delivery can be achieved using N -acetylgalactosamine conjugation and/or lipid nanoparticles. Emerging approaches include stereopure oligonucleotide chemistry, circular RNAs, adenosine-to-inosine RNA base editing, and nonhepatic targeting. This review summarizes the mechanistic basis of each modality, the clinical evidence for approved cardiovascular RNA therapeutics, selected pipeline candidates in advanced trials, and directions for future development.

doi.org/10.1146/annurev-med-042425-070657PubMed 43038382Interventions

AgingResearch.News